利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.022 秒)

    Sustained release formulations of oxymorphone
    2.
    发明申请
    Sustained release formulations of oxymorphone 审中-公开
    羟吗啡酮的缓释制剂

    公开(公告)号：US20080050431A1

    公开(公告)日：2008-02-28

    申请号：US11891775

    申请日：2007-08-13

    申请人： Anand Baichwal ,  Huai-Hung Kao ,  Troy McCall

    发明人： Anand Baichwal ,  Huai-Hung Kao ,  Troy McCall

    IPC分类号： A61K9/22 ,  A61K31/485 ,  A61P29/00

    CPC分类号： A61K31/485 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054

    摘要： Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

    摘要翻译： 羟吗啡酮或其药学上可接受的盐的缓释制剂; 制备羟吗啡酮缓释制剂或其药学上可接受的盐的方法; 提供了使用羟吗啡酮的缓释制剂或其药学上可接受的盐来治疗患有疼痛的患者的方法。

    ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM
    8.
    发明申请
    ABUSE-RESISTANT CONTROLLED-RELEASE OPIOID DOSAGE FORM 审中-公开
    耐药控制释放OPIOID剂型

    公开(公告)号：US20120252832A1

    公开(公告)日：2012-10-04

    申请号：US13494431

    申请日：2012-06-12

    申请人： Frank S. Caruso ,  Huai-Hung Kao

    发明人： Frank S. Caruso ,  Huai-Hung Kao

    IPC分类号： A61K31/46

    CPC分类号： A61K31/485 ,  A61K9/0002 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/46 ,  A61K2300/00

    摘要： Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as an immediate release product as a single dose. The controlled release nature of the tablet prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.

    摘要翻译： 滥用耐药的控释阿片类药物是含有阿片样物质拮抗剂如纳洛酮的组合，其水平高于抑制阿片样物质的欣快作用所需的水平，如果组合被粉碎以破坏控制释放性质，导致阿片样物质和阿片样物质拮抗剂 作为单次剂量的即时释放产品释放。 片剂的控制释放性质可防止口服有效量的阿片样物质拮抗剂在正常服用时积聚。 阿片类拮抗剂包含在控释基质中，随着时间的推移与阿片样物质一起释放。

    Sustained release oxycodone composition with acrylic polymer and surfactant
    10.
    发明申请
    Sustained release oxycodone composition with acrylic polymer and surfactant 审中-公开
    具有丙烯酸聚合物和表面活性剂的缓释羟考酮组合物

    公开(公告)号：US20070281016A1

    公开(公告)日：2007-12-06

    申请号：US11447560

    申请日：2006-06-06

    申请人： Huai-Hung Kao ,  Sou-Chan Chang ,  Yadi Zeng ,  Fai Jim

    发明人： Huai-Hung Kao ,  Sou-Chan Chang ,  Yadi Zeng ,  Fai Jim

    IPC分类号： A61K31/485 ,  A61K9/22

    CPC分类号： A61K31/485 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054

    摘要： The invention is a controlled release composition comprising a therapeutic amount of an active ingredient in a controlled release matrix. The matrix comprises a combination of a pharmaceutically acceptable acrylic polymer and a metal hydroxide. The amount of surfactant, relative to a given amount of acrylic polymer, is selected for and corresponds to a predetermined release rate for said active ingredient. The compound is preferably used to provide controlled release dosage of oxycodone through a matrix of ammonio methacrylic polymer and sodium lauryl sulfate.

    摘要翻译： 本发明是一种控释组合物，其包含治疗量的受控释放基质中的活性成分。 基质包含药学上可接受的丙烯酸类聚合物和金属氢氧化物的组合。 选择相对于给定量的丙烯酸类聚合物的表面活性剂的量并且对应于所述活性成分的预定释放速率。 该化合物优选用于通过氨基甲基丙烯酸聚合物和月桂基硫酸钠的基质提供羟考酮的控制释放剂量。